Also listed on Recro Pharma, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Mar 8, 2039 · High confidence
20-year base term ends Mar 8, 2039
Held by Alkermes Pharma Ireland Limited
Filed Mar 8, 2019 as application 16/297,095 · Granted Oct 4, 2022
Base term, 20 years from filing
Today
2019
2039
Clock starts
Mar 8, 2019
Mar 8, 2019
Term ends
Mar 8, 2039
Mar 8, 2039
Granted
Oct 4, 2022
Oct 4, 2022
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 10,881,663, to Mar 8, 2039. The term already ends on or before that date, so the cap shortened nothing.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
3
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 3 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 8, 2019, when this application, 16/297,095, was filed | Mar 8, 2039 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,881,663) | resolves to Mar 8, 2039, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Mar 8, 2039 | High confidence |
This family
| US 11,458,145 | this patent Mar 2039 | Mar 2039 |
| US 10,881,663 | In force Mar 2039 | Mar 2039 |
| Application 17/820,783 | Abandoned not computed | not computed |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 8, 2019 Reel 50960, frame 857 | Mack, Randall J.; Freyer, Alex | Recro Pharma, Inc. | Assignment of Assignor's Interest |
| Jan 30, 2020 Reel 51758, frame 130 | Recro Pharma, Inc. | Baudax Bio, Inc. | Assignment of Assignor's Interest |
| Jun 10, 2020 Reel 52891, frame 590 | Baudax Bio N.A. LLC; Baudax Bio Limited; Baudax Bio, Inc. | Wilmington Trust, National Association | Security Interest |
| Mar 29, 2023 Reel 63189, frame 142 | Wilmington Trust, National Association, as Agent | Baudax Bio, Inc.; Baudax Bio N.A. LLC; Baudax Bio Limited | Partial Release of Intellectual Property Security Agreement |
| Mar 29, 2023 reel/frame not recorded | Wilmington Trust, National Association, as Agent | Baudax Bio, Inc. | Partial Release of Intellectual Property Security Agreement |
| Mar 29, 2023 reel/frame not recorded | Wilmington Trust, National Association, as Agent | Baudax Bio N.A. LLC | Partial Release of Intellectual Property Security Agreement |
| Mar 29, 2023 reel/frame not recorded | Wilmington Trust, National Association, as Agent | Baudax Bio Limited | Partial Release of Intellectual Property Security Agreement |
| May 23, 2023 Reel 63736, frame 279 | Baudax Bio, Inc. | Alkermes Pharma Ireland Limited | Assignment of Assignor's Interest |
| Oct 23, 2025 Reel 73213, frame 302 | Alkermes Pharma Ireland Limited | JPMorgan Chase Bank, N.A. as Administrative Agent | Security Interest |
| Feb 13, 2026 Reel 74858, frame 405 | Alkermes Pharma Ireland Limited | JPMorgan Chase Bank, N.A. as Administrative Agent | Security Interest |
| Feb 13, 2026 Reel 74858, frame 429 | JPMorgan Chase Bank, N.A., as Administrative Agent | Alkermes Pharma Ireland Limited | Release of Security Interest in Patents Previously Recorded at Reel/Frame (073213/0302) |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Mar 2039
Term ends Mar 8, 2039. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 10,881,663, ends no earlier than this term, so it caps nothing.
Citations
1
later US patent cites this one
That is below the median of utility patents granted in 2022 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.